Envista Holdings Co. (NYSE:NVST) SVP Mischa Reis sold 10,016 shares of the business’s stock in a transaction on Friday, August 27th. The shares were sold at an average price of $42.50, for a total transaction of $425,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NYSE NVST traded up $1.27 on Friday, hitting $42.67. 1,361,036 shares of the company were exchanged, compared to its average volume of 1,872,084. The firm’s 50 day simple moving average is $42.09. The company has a market cap of $6.88 billion, a P/E ratio of 23.97, a P/E/G ratio of 0.76 and a beta of 1.93. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 0.23. Envista Holdings Co. has a 1-year low of $22.51 and a 1-year high of $46.52.
Envista (NYSE:NVST) last issued its quarterly earnings results on Tuesday, August 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.09. The business had revenue of $740.10 million for the quarter, compared to the consensus estimate of $705.75 million. Envista had a net margin of 10.84% and a return on equity of 9.72%. On average, analysts expect that Envista Holdings Co. will post 1.96 EPS for the current fiscal year.
NVST has been the topic of several analyst reports. TheStreet raised shares of Envista from a “d+” rating to a “c” rating in a report on Thursday, May 13th. Credit Suisse Group boosted their price target on shares of Envista from $49.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, May 6th. Morgan Stanley boosted their target price on shares of Envista from $42.00 to $46.00 and gave the company an “equal weight” rating in a research note on Friday, May 7th. Piper Sandler boosted their target price on shares of Envista from $45.00 to $47.00 and gave the company a “neutral” rating in a research note on Wednesday, August 4th. Finally, Zacks Investment Research upgraded shares of Envista from a “hold” rating to a “strong-buy” rating and set a $52.00 target price on the stock in a research note on Saturday, May 8th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $43.67.
A number of large investors have recently made changes to their positions in NVST. Dimensional Fund Advisors LP raised its holdings in Envista by 11.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,683,495 shares of the company’s stock worth $124,240,000 after purchasing an additional 378,540 shares during the last quarter. Strs Ohio raised its holdings in Envista by 36.6% during the 1st quarter. Strs Ohio now owns 34,573 shares of the company’s stock worth $1,410,000 after purchasing an additional 9,264 shares during the last quarter. Oliver Luxxe Assets LLC bought a new stake in Envista during the 1st quarter worth about $1,574,000. CAPROCK Group Inc. bought a new stake in Envista during the 1st quarter worth about $253,000. Finally, Convergence Investment Partners LLC bought a new stake in shares of Envista in the 1st quarter valued at about $252,000.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Featured Article: How to Invest in the Dividend Aristocrat Index
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Envista right now?
Before you consider Envista, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Envista wasn’t on the list.
While Envista currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
